Monitor for any subsequent announcements of definitive partnership agreements or clinical data readouts from the BIO convention. The lack of new financial or clinical catalysts keeps the stock in a low-liquidity, binary-risk environment dominated by dilution concerns.
Price Chart
Executive Summary
Can-Fite announced its participation in the BIO International Convention 2026 (June 22-25) to conduct partnering meetings for its late-stage pipeline, including Namodenoson (Phase III HCC, Phase IIb MASH) and Piclidenoson (Phase III psoriasis). No new clinical data, financial results, or definitive partnership agreements were disclosed. The $6M market cap and high cash burn rate suggest dilution risk remains the dominant concern, making this routine conference attendance with no material impact.
Key Facts
- Can-Fite will attend BIO International Convention 2026 from June 22-25 in San Diego for partnering meetings.
- Pipeline includes Namodenoson (Phase III HCC, Phase IIb MASH, Phase IIa pancreatic cancer) and Piclidenoson (Phase III psoriasis).
- Prior licensing agreements have generated approximately $20 million in upfront and milestone payments.
- No new clinical data, regulatory approvals, or financial disclosures were provided.
- Market cap is $6M with no disclosed cash runway or revenue.
Financial Impact
No new financial data disclosed. Prior licensing agreements generated ~$20M in cumulative upfront and milestone payments.
Risk Factors
- No new capital or cash runway disclosed; pre-revenue biotech with ongoing cash burn.
- Failure to secure new licensing partnerships could prolong dilution risk.
- Pivotal Phase III data readouts for Namodenoson and Piclidenoson remain key binary catalysts with significant downside if negative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-069431 |
| Document: ea029496501-6k_canfite.htm | 0001213900-26-069431 |
| Document: 0001213900-26-069431-index-headers.html | 0001213900-26-069431 |
| Document: 0001213900-26-069431-index.html | 0001213900-26-069431 |
| Document: 0001213900-26-069431.txt | 0001213900-26-069431 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.95 | awaiting T+5 | — | $1.72 (−11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.72 (+25.22%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.72 (−21.46%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.72 (−26.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.72 (+27.12%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.72 (−51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers